Pub Date : 2026-01-18DOI: 10.1016/j.healun.2026.01.012
Julia Baranowska, Gabriel Sayer, Nir Uriel
{"title":"Efficacy and Safety of Belatacept in Heart Transplant Recipients - Invited Response to a Letter to the Editor","authors":"Julia Baranowska, Gabriel Sayer, Nir Uriel","doi":"10.1016/j.healun.2026.01.012","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.012","url":null,"abstract":"","PeriodicalId":22654,"journal":{"name":"The Journal of Heart and Lung Transplantation","volume":"225 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145995279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-16DOI: 10.1016/j.healun.2026.01.008
A C Bhowmik,B Wayda,Y Weng,S Zhang,N Neidlinger,K K Khush
PURPOSEPerformance of invasive coronary angiography (ICA) to screen for coronary artery disease (CAD) in younger potential heart donors is discretionary and thus may vary across regions. We examined the variation, predictors, and outcomes of ICA in potential heart donors in the United States.METHODSUsing the Scientific Registry of Transplant Recipients (SRTR), our cohort included brain-dead potential heart donors from 2018 to 2023. Older donors (> 50 years for men, > 55 for women) were excluded; the remainder were stratified as young (< 35) or middle-aged. We further stratified by "low" or "high" CAD risk; the latter was defined by a history of diabetes or ≥ 2 other non-age risk factors. We characterized temporal and geographic variation and predictors of ICA using multivariable logistic regression. We also characterized the prevalence of significant CAD (any ≥ 50% stenosis) among donors who received ICA.RESULTSOf 11,897 young and 8,936 middle-aged donors, 2443 (20.5%) and 5272 (59.0%), respectively, received ICA. Coronary angiogram performance increased over time and was highest in New England for both groups. Among CAD risk factors, diabetes (in young donors only), age, smoking, and cocaine use were predictive of ICA utilization. Among young low-risk, young high-risk, middle-aged low-risk, and middle-aged high-risk donors who received coronary angiography, 1%, 2%, 3%, and 7%, respectively, had significant CAD.CONCLUSIONSICA is performed in 20% of young potential heart donors, varies widely by region, and rarely identifies significant CAD in young or otherwise low risk donors. Standardized protocols are needed to rationalize its use.
{"title":"Trends, variation, and predictors of coronary angiography in potential cardiac organ donors.","authors":"A C Bhowmik,B Wayda,Y Weng,S Zhang,N Neidlinger,K K Khush","doi":"10.1016/j.healun.2026.01.008","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.008","url":null,"abstract":"PURPOSEPerformance of invasive coronary angiography (ICA) to screen for coronary artery disease (CAD) in younger potential heart donors is discretionary and thus may vary across regions. We examined the variation, predictors, and outcomes of ICA in potential heart donors in the United States.METHODSUsing the Scientific Registry of Transplant Recipients (SRTR), our cohort included brain-dead potential heart donors from 2018 to 2023. Older donors (> 50 years for men, > 55 for women) were excluded; the remainder were stratified as young (< 35) or middle-aged. We further stratified by \"low\" or \"high\" CAD risk; the latter was defined by a history of diabetes or ≥ 2 other non-age risk factors. We characterized temporal and geographic variation and predictors of ICA using multivariable logistic regression. We also characterized the prevalence of significant CAD (any ≥ 50% stenosis) among donors who received ICA.RESULTSOf 11,897 young and 8,936 middle-aged donors, 2443 (20.5%) and 5272 (59.0%), respectively, received ICA. Coronary angiogram performance increased over time and was highest in New England for both groups. Among CAD risk factors, diabetes (in young donors only), age, smoking, and cocaine use were predictive of ICA utilization. Among young low-risk, young high-risk, middle-aged low-risk, and middle-aged high-risk donors who received coronary angiography, 1%, 2%, 3%, and 7%, respectively, had significant CAD.CONCLUSIONSICA is performed in 20% of young potential heart donors, varies widely by region, and rarely identifies significant CAD in young or otherwise low risk donors. Standardized protocols are needed to rationalize its use.","PeriodicalId":22654,"journal":{"name":"The Journal of Heart and Lung Transplantation","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15DOI: 10.1016/j.healun.2026.01.009
Matthew M Cooper
{"title":"Is RNA the Rosetta Stone for Organ Preservation?","authors":"Matthew M Cooper","doi":"10.1016/j.healun.2026.01.009","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.009","url":null,"abstract":"","PeriodicalId":22654,"journal":{"name":"The Journal of Heart and Lung Transplantation","volume":"269 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145993028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1016/j.healun.2026.01.015
David A Baran
{"title":"No Longer in Hiding: Post Cardiotomy Shock.","authors":"David A Baran","doi":"10.1016/j.healun.2026.01.015","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.015","url":null,"abstract":"","PeriodicalId":22654,"journal":{"name":"The Journal of Heart and Lung Transplantation","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145986560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1016/j.healun.2026.01.007
Michele Gallo, Mark S. Slaughter
{"title":"Transcutaneous energy transfer system for Left Ventricular Assist Device support: current challenges and new technology","authors":"Michele Gallo, Mark S. Slaughter","doi":"10.1016/j.healun.2026.01.007","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.007","url":null,"abstract":"","PeriodicalId":22654,"journal":{"name":"The Journal of Heart and Lung Transplantation","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145962498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1016/j.healun.2026.01.010
Laurence Dewachter, Jean-Luc Vachiéry
{"title":"Same Pressure, Different Disease: A Proteomic Rethinking of Pulmonary Hypertension in Chronic Lung Disease","authors":"Laurence Dewachter, Jean-Luc Vachiéry","doi":"10.1016/j.healun.2026.01.010","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.010","url":null,"abstract":"","PeriodicalId":22654,"journal":{"name":"The Journal of Heart and Lung Transplantation","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145962450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1016/j.healun.2025.12.025
Khalil Nassar, Lourdes Cabrera, Donald S. Likosky, Keith D Aaronson, Ahmad M. Hider, Francis D Pagani
{"title":"Algorithm to Reduce Inter-Rater Variability in Assessment of Intermacs Patient Profiles","authors":"Khalil Nassar, Lourdes Cabrera, Donald S. Likosky, Keith D Aaronson, Ahmad M. Hider, Francis D Pagani","doi":"10.1016/j.healun.2025.12.025","DOIUrl":"https://doi.org/10.1016/j.healun.2025.12.025","url":null,"abstract":"","PeriodicalId":22654,"journal":{"name":"The Journal of Heart and Lung Transplantation","volume":"86 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145961669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-09DOI: 10.1016/j.healun.2026.01.003
Mohammed Tiseer Abbas,Juan M Farina,Omar H Ibrahim,Sherif Ahmed,Nadera N Bismee,Kamal Awad,Fares Jamal,Hesham Sheashaa,Milagros Pereyra Pietri,Isabel G Scalia,Nima Baba Ali,Sogol Attaripour Esfahani,Fatmaelzahraa E Abdelfattah,Mahshad Razaghi,Ahmed K Mahmoud,Ramzi Ibrahim,D Eric Steidley,Julie L Rosenthal,Lisa M LeMond,Robert L Scott,Brian W Hardaway,Francis X Downey,Kristen A Sell-Dottin,Parag C Patel,Alfredo L Clavell,Chadi Ayoub,Reza Arsanjani
BACKGROUNDGlucagon-like peptide 1 receptor agonists (GLP-1RAs) have demonstrated survival benefits and cardioprotective effects in diabetic and heart failure (HF) patients. However, the association of GLP-1RAs use with mortality and morbidity in heart transplant (HT) recipients has not been previously investigated.METHODSAll adult patients who underwent HT at three Mayo Clinic sites and survived at least one month after the procedure were assessed. GLP-1RAs use was extracted retrospectively from the electronic medical records (EMR) after the HT. All-cause mortality and hospitalization due to graft dysfunction, graft rejection, vasculopathy, de novo DM, and dialysis were collected and compared between patients exposed and non-exposed to GLP-1RA using Kaplan-Meier curves, cumulative incidence functions, and multivariate Cox regression analyses incorporating GLP-1RA exposure as a time varying covariate.RESULTSA total of 1914 patients were included with a median age of 56.3 (46.1, 62.8) years and 71.2 % were male. The median follow up was 5.5 (2.2,10.2) years and 285 (14.9 %) used GLP-1RAs following HT. In the multivariable time-dependent Cox analysis, GLP-1RA therapy was associated with lower risk of all-cause mortality (HR: 0.33, 95 % CI: 0.12 to 0.90; p = 0.031), but not with hospitalization due to graft dysfunction (HR: 0.95, 95 % CI: 0.45 to 2.01; p = 0.900) or other outcomes through 5-year follow-up.CONCLUSIONSTherapy with GLP-1RAs was associated with a lower risk of all-cause mortality in HT recipients. While the mechanisms of these associations need further investigations, these findings, suggest a potential therapeutic role to improve survival after HT.
{"title":"The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant.","authors":"Mohammed Tiseer Abbas,Juan M Farina,Omar H Ibrahim,Sherif Ahmed,Nadera N Bismee,Kamal Awad,Fares Jamal,Hesham Sheashaa,Milagros Pereyra Pietri,Isabel G Scalia,Nima Baba Ali,Sogol Attaripour Esfahani,Fatmaelzahraa E Abdelfattah,Mahshad Razaghi,Ahmed K Mahmoud,Ramzi Ibrahim,D Eric Steidley,Julie L Rosenthal,Lisa M LeMond,Robert L Scott,Brian W Hardaway,Francis X Downey,Kristen A Sell-Dottin,Parag C Patel,Alfredo L Clavell,Chadi Ayoub,Reza Arsanjani","doi":"10.1016/j.healun.2026.01.003","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.003","url":null,"abstract":"BACKGROUNDGlucagon-like peptide 1 receptor agonists (GLP-1RAs) have demonstrated survival benefits and cardioprotective effects in diabetic and heart failure (HF) patients. However, the association of GLP-1RAs use with mortality and morbidity in heart transplant (HT) recipients has not been previously investigated.METHODSAll adult patients who underwent HT at three Mayo Clinic sites and survived at least one month after the procedure were assessed. GLP-1RAs use was extracted retrospectively from the electronic medical records (EMR) after the HT. All-cause mortality and hospitalization due to graft dysfunction, graft rejection, vasculopathy, de novo DM, and dialysis were collected and compared between patients exposed and non-exposed to GLP-1RA using Kaplan-Meier curves, cumulative incidence functions, and multivariate Cox regression analyses incorporating GLP-1RA exposure as a time varying covariate.RESULTSA total of 1914 patients were included with a median age of 56.3 (46.1, 62.8) years and 71.2 % were male. The median follow up was 5.5 (2.2,10.2) years and 285 (14.9 %) used GLP-1RAs following HT. In the multivariable time-dependent Cox analysis, GLP-1RA therapy was associated with lower risk of all-cause mortality (HR: 0.33, 95 % CI: 0.12 to 0.90; p = 0.031), but not with hospitalization due to graft dysfunction (HR: 0.95, 95 % CI: 0.45 to 2.01; p = 0.900) or other outcomes through 5-year follow-up.CONCLUSIONSTherapy with GLP-1RAs was associated with a lower risk of all-cause mortality in HT recipients. While the mechanisms of these associations need further investigations, these findings, suggest a potential therapeutic role to improve survival after HT.","PeriodicalId":22654,"journal":{"name":"The Journal of Heart and Lung Transplantation","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145949579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-08DOI: 10.1016/j.healun.2026.01.002
Nicholas J S Chilvers,Louise Kenny
{"title":"Reply to \"Assessing Patient Selection and Scalability in Pediatric DCD Heart Transplantation: A Critical Appraisal of HOPE Outcomes. Comment on Chilvers et al\".","authors":"Nicholas J S Chilvers,Louise Kenny","doi":"10.1016/j.healun.2026.01.002","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.002","url":null,"abstract":"","PeriodicalId":22654,"journal":{"name":"The Journal of Heart and Lung Transplantation","volume":"253 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：